Table 1.
Demographics per predefined vaccination group.
| Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | |
|---|---|---|---|---|---|
| Number of patients | 2144 | 1532 | 1283 | 147 | 40 |
| Mean age yo (SD) | 44.6 (35.5) | 46.9 (30.8) | 46.6 (32.7) | 51.0 (15.7) | 39.4 (14.4) |
| Age category | |||||
| <60 yo | 1550 (72.3%) | 1084 (70.8%) | 930 (72.5%) | 98 (66.7%) | 35 (87.5%) |
| >/=60 yo | 463 (21.6%) | 417 (27.2%) | 341 (26.6%) | 49 (33.3%) | 5 (12.5%) |
| Male/female | 1088 (51.0%)/1047 (49.0%) | 794 (51.9%)/737 (48.1%) | 661 (51.6%)/621 (48.4%) | 80 (54.4%)/67 (45.6%) | 24 (60.0%)/16 (40%) |
| BMI in kg/m2 (mean (SD)) | 26.1 (4.95) | 26.2 (5.06) | 26.4 (4.72) | 26.7 (5.14) | 23.8 (3.63) |
| <18.5 kg/m2 | 54 (2.8%) | 30 (2.3%) | 20 (1.8%) | 5 (4.1%) | 1 (2.8%) |
| 18–25 kg/m2 | 807 (42.0%) | 553 (42.5%) | 424 (38.9%) | 41 (33.3%) | 21 (58.3%) |
| 25–30 kg/m2 | 691 (35.9%) | 465 (35.7%) | 429 (39.4%) | 49 (39.8%) | 11 (30.6%) |
| >30 kg/m2 | 371 (19.3%) | 254 (19.5%) | 217 (19.9%) | 28 (22.8%) | 3 (8.3%) |
| >25 kg/m2 | 1062 (49.5%) | 750 (49.0%) | 656 (51.1%) | 82 (55.8%) | 12 (32.5%) |
| Comorbidities | |||||
| Heart disease | 200 (9.33%) | 173 (11.3%) | 120 (9.35%) | 27 (18.4%) | 1 (2.5%) |
| Chronic pulmonary disease (not asthma) | 63 (2.94%) | 57 (3.72%) | 38 (2.96%) | 7 (4.76%) | 2 (5%) |
| Asthma | 73 (3.4%) | 51 (3.33%) | 53 (4.13%) | 8 (5.44%) | 3 (7.50%) |
| CKD | 49 (2.29%) | 46 (3.00%) | 41 (3.20% | 4 (2.72%) | 2 (5.00%) |
| Chronic liver disease | 75 (3.50%) | 90 (5.87%) | 69 (5.38%) | 7 (4.76%) | 3 (7.50%) |
| Neurologic disease | 44 (2.05%) | 54 (3.52%) | 47 (3.66%) | 8 (5.44%) | 0 |
| Malignancy (history or active) | 111 (5.18%) | 83 (5.42%) | 82 (6.39%) | 2 (1.36%) | 0 |
| Hematologic disease | 45 (2.10%) | 45 (2.94%) | 28 (2.18%) | 5 (3.40%) | 2 (5.00%) |
| HIV | 2 (0.09%) | 2 (0.13%) | 2 (0.16%) | 0 | 0 |
| Diabetes mellitus | 97 (4.52%) | 78 (5.09%) | 69 (5.38%) | 7 (4.76%) | 1 (2.50%) |
| No comorbidities | 565 (26.4%) | 388 (25.3%) | 277 (21.6%) | 42(28.6%) | 9 (22.5%) |
| Active smoker | 369 (17.2%) | 261 (17.0%) | 201 (15.7%) | 24 (16.3%) | 12 (30.0%) |
| Increased COVID-19 exposure risk * | 1019 (47.5%) | 621 (40.5%) | 69 (49.8%) | 80 (54.4%) | 23 (57.5%) |
| IMID type | |||||
| Dermatologic | 310 (14.5%) | 239 (15.6%) | 139 (10.8%) | 42 (28.6%) | 5 (12.5%) |
| HS | 36 (12.2%) | 21 (8.8%) | 17 (12.4%) | 2 (4.8%) | 1 (20%) |
| Pso | 226 (76.6%) | 195 (81.6%) | 100 (73.0%) | 37 (88.1%) | 4 (80.0%) |
| Atopic derm | 33 (11.2%) | 20 (14.6%) | 20 (14.6%) | 3 (7.1%) | 0 |
| Gastro/IBD | 1336 (62.3%) | 982 (64.1%) | 920 (71.7%) | 65 (44.2%) | 31 (77.5%) |
| CD | 838 (64.9%) | 644 (66.3%) | 589 (64.3%) | 46 (71.9%) | 19 (61.3%) |
| UC | 404 (31.3%) | 294 (30.2%) | 295 (32.2%) | 16 (25.0%) | 12 (38.7%) |
| IPAA | 37 (2.9%) | 25 (2.6%) | 25 (2.7% | 1 (1.6%) | 0 |
| Undifferentiated colitis | 13 (1.0%) | 9 (0.9%) | 7 (0.8%) | 1 (1.6%) | 0 |
| Rheumatologic | 498 (23.2%) | 311 (20.3%) | 224 (17.5%) | 40 (27.2%) | 4 (10.0%) |
| RA | 256 (56.0%) | 179 (60.1%) | 127 (58.0%) | 24 (61.5%) | 2 (50.0%) |
| SpA | 126 (27.6%) | 61 (20.5%) | 43 (19.6%) | 5 (12.8%) | 2 (50.0%) |
| PsoA | 75 (16.4%) | 58 (19.5%) | 49 (22.4%) | 10 (25.6%) | 0 |
| IMID-treatment modality | |||||
| TIMT | 1580 (73.7%) | 1232 (80.4%) | 1073 (83.6%) | 119 (81.0%) | 38 (95.0%) |
| Infliximab | 503 (23.5%) | 394 (25.7%) | 376 (29.3%) | 23 (15.6%) | 17 (42.5%) |
| Anti-TNF alpha | 783 (36.5%) | 594 (38.8%) | 523 (40.8%) | 60 (40.8%) | 21 (52.5%) |
| Vedolizumab | 328 (15.3%) | 260 (17.0%) | 270 (21.1%) | 9 (6.1%) | 7 (17.5%) |
| Rituximab | 36 (1.7%) | 23 (1.5%) | 20 (1.6%) | 1 (0.7%) | 0 |
| Anti-IL12/23/17 (grouped) | 280 (13.1%) | 228 (14.9%) | 156 (12.2%) | 40 (27.2%) | 5 (12.5%) |
| Anti-IL12/23 (grouped) | 199 (9.3%) | 162 (10.6%) | 119 (9.3%) | 25 (17.0%) | 3 (7.5%) |
| Anti-IL17 | 83 (3.9%) | 66 (4.3%) | 38 (3.0%) | 15 (10.2%) | 2 (5.0%) |
| Anti-IL23 | 69 (3.2%) | 60 (3.9%) | 29 (2.3%) | 14 (9.5%) | 1 (2.5%) |
| JAK-inhibitor | 34 (1.6%) | 36 (2.3%) | 23 (1.8%) | 1 (0.7%) | 1 (0.7%) |
| IMM | 456 (21.3%) | 311 (20.3%) | 225 (17.5%) | 39 (26.5%) | 8 (20.0%) |
| Combined TIMT + IMM | 263 (12.3%) | 197 (12.9%) | 152 (11.8%) | 24 (16.3%) | 8 (20.0%) |
| N-IM (= non-TIMT/non-IMM at baseline) | 113 (5.3%) | 64 (4.2%) | 44 (3.4%) | 4 (2.7%) | 1 (2.5%) |
| Received systemic steroids | 229 (10.7%) | 91 (5.94%) | 59 (4.60%) | 6 (4.08%) | 4 (10.0%) |
| No active IMID disease ** during time period 1 | 1309 (61.05%) | 1035 (67.56%) | 951 (74.12%) | 93 (63.27%) | 31 (77.5%) |
Abbreviations: yo: years old, SD: standard deviation, BMI: body mass index, CKD: chronic kidney disease, HIV: human immunodeficiency virus seropositivity, IMID: immune mediated inflammatory disease, HS: hidradenitis suppurativa, Pso: psoriasis, atopic derm(atitis), CD: Crohn’s disease, UC: ulcerative colitis, IPAA: ileal pouch anal anastomosis (post colectomy), RA: rheumatoid arthritis, SpA: spondyloarthritis, PsoA: psoriatic arthritis, TIMT: targeted immune-modulating treatment, IMM: immunomodulator, TNF: tumor necrosis factor, IL: interleukin, JAK: Janus kinase, PCR: polymerase chain reaction. * SARS-CoV-2 exposure risk was considered increased based on patients’ job description, recent travelling history or potential COVID-19 contact at healthcare facilities. ** Active disease: according to treating physician and/or based on patient reported outcome scores and/or requirement of steroid treatment and/or requirement of IMID-induced hospitalization.